Correlation found between change in IOP and conjunctival hyperaemia induced by latanoprost

Article

A strong correlation between a change in intraocular pressure (IOP) and conjunctival hyperaemia severity induced by latanoprost has been confirmed in a recent study.

A strong correlation between a change in intraocular pressure (IOP) and conjunctival hyperaemia severity induced by latanoprost has been confirmed in a recent study published in the Journal of Glaucoma.

Drs Hiroshi and Kaori Kobayashi, from Amagasaki Hospital, Hyogo and Osaka Red Cross Hospital, Osaka, Japan, respectively, examined 114 patients with open-angle glaucoma or ocular hypertension. Their aim was to determine any correlation between a short-term change in conjunctival hyperaemia severity and the IOP-reducing effect induced by latanoprost.

Of the 114 patients 56 were female and 58 were male and they had a mean age of 60.9±15 years. The primary outcome of the study was to determine the change in conjunctival hyperaemia grade at day 2 and the change in IOP at 6 months after commencing latanoprost treatment.

The mean IOP before latanoprost treatment was 22.5±3.8 mmHg and after 6 months it was 16.5±2.9 mmHg (P < 0.0001). Mean changes in conjunctival hyperaemia before and after 2 days of latanoprost treatment were 0.32±0.58 and 1.74±1.11, respectively (P < 0.0001). It was found that the mean change in IOP was greater in eyes with a higher hyperaemia grade change.

In conclusion, the researchers found a significant correlation between the change in IOP and the conjunctival hyperaemia severity after treatment with latanoprost.

Related Videos
A screenshot of Dr Filomena Ribeiro, president of the ESCRS
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.